CASI Pharmaceuticals, Inc. (CASI)
$
1.88
-0.04 (-2.13%)
Key metrics
Financial statements
Free cash flow per share
0
Market cap
29 Million
Price to sales ratio
1.0152
Debt to equity
11.9616
Current ratio
1.0857
Income quality
0
Average inventory
9.1 Million
ROE
-3.9076
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
CASI Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics and pharmaceutical products across China, the United States, and other international markets. The company’s key offerings include EVOMELA, an intravenous formulation of melphalan utilized as a conditioning treatment prior to stem cell transplantation and as a palliative option for patients with multiple myeloma. Its robust product pipeline features CNCT19, an autologous CD19 CAR-T investigative therapy targeting B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. Additionally, BI-1206 is in Phase I/II trials, assessed in combination with the anti-PD1 therapy Keytruda for solid tumors, as well as in a Phase I/IIa study alongside MabThera (rituximab) for patients with relapsed/refractory NHL. CB-5339, currently undergoing Phase I clinical trials for acute myeloid leukemia and myelodysplastic syndrome, adds to the pipeline's diversity. Other investigational products include CID-103 for multiple myeloma treatment; Thiotepa, with various indications as a conditioning treatment for allogeneic hematopoietic stem cell transplants; and long-acting injectable formulations of Octreotide for managing acromegaly and neuroendocrine tumor symptoms. The company's strategic collaborations extend to licensing agreements with Juventas Cell Therapy Ltd, BioInvent International AB, Black Belt Therapeutics Limited, and Cleave Therapeutics, Inc. Distribution agreements are established with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, Pharmathen Global BV, and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was previously known as EntreMed, Inc. before rebranding in June 2014, and it was incorporated in 1991 in Rockville, Maryland. The net total of other income and expenses is $1,552,000.00 reflecting non-core financial activities. The EBITDA stands at -$34,867,000.00 which serves as a vital indicator of the company's operational profitability. The diluted EPS is -$2.56 accounting for potential share dilution, while the cost of revenue for the company totals $17,391,000.00 showcasing its production and operational expenses. The EBITDA ratio is -$1.22 highlighting the company's operational efficiency. Currently, the stock is affordable at $1.88 making it suitable for budget-conscious investors. It exhibits a low average trading volume of 9,301.00 indicating lower market activity. With a market capitalization of $29,067,404.00 the company is categorized as a small-cap player. CASI Pharmaceuticals, Inc. serves as a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It actively participates in the Healthcare sector, driving innovation and growth while aligning its strategic initiatives to meet evolving market needs.
Is CASI Pharmaceuticals, Inc. (CASI) a good investment?
Investing in CASI Pharmaceuticals, Inc. (CASI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is CASI Pharmaceuticals, Inc. (CASI)'s stock forecast?
Analysts predict CASI Pharmaceuticals, Inc. stock to fluctuate between $1.64 (low) and $7.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is CASI Pharmaceuticals, Inc.'s market capitalization?
As of 2025-05-29, CASI Pharmaceuticals, Inc.'s market cap is $29,067,404, based on 15,492,700 outstanding shares.
How does CASI Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., CASI Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy CASI Pharmaceuticals, Inc. (CASI) stock?
To buy CASI Pharmaceuticals, Inc. (CASI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CASI. Place an order (Market, Limit, etc.).
What is the best time to invest in CASI Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has CASI Pharmaceuticals, Inc. stock ever split?
CASI Pharmaceuticals, Inc.'s last stock split was 1:10 on 2022-06-02.
How did CASI Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $28,537,000 | EPS: -$2.56 | Growth: 26.73%.
Where can I find CASI Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.casipharmaceuticals.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for CASI Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for CASI Pharmaceuticals, Inc. stock?
All-time high: $36.80 (2021-02-03) | All-time low: $1.45 (2022-12-27).
What are the key trends affecting CASI Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
11 days ago
BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that it will host a live conference call and webcast at 8:00 a.m. PT/11:00 a.m.
accessnewswire.com
14 days ago
BEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the quarter ended March 31, 2025. Dr. Wei-Wu He, Ph.D.
accessnewswire.com
18 days ago
BEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has entered into a definitive Equity and Assets Transfer Agreement (the "Equity and Assets Transfer Agreement") with Kaixin Pharmaceuticals Inc. ("Kaixin Pharmaceuticals"), a Cayman Islands incorporated entity wholly-owned by Dr. Wei-Wu He, Chairman of the board of directors and CEO of the Company and two direct wholly-owned subsidiaries of the Company in China (the "Target Companies"), pursuant to which the Company shall sell and transfer, and Kaixin Pharmaceuticals shall purchase and acquire, 100% equity interests in both Target Companies (the "Target Equity Interests"), and all licensing rights, distribution rights, supply arrangements and related rights related to BI-1206 (in China), CID-103(in Asia excluding Japan) and Thiotepa (in China excluding Hong Kong, Macau and Taiwan) (the "Target Pipeline Products") for an aggregate purchase price of $20.0 million, which shall include assumption of up to $20.0 million of indebtedness of the Company (the "Transaction"). The closing of the Transaction shall be subject to certain customary conditions, including resolution of certain judicial freeze on the Target Equity Interests issued in connection with certain ongoing legal dispute of the Company.
accessnewswire.com
23 days ago
BEIJING, CHINA / ACCESS Newswire / May 7, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated May 5, 2025 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities ("MVLS") of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum MVLS of $35 million (the "MVLS Requirement"), and Nasdaq Listing Rule 5810(c)(3)(C) specifies that a deficiency occurs if the MVLS falls below this threshold for 30 consecutive business days.
accessnewswire.com
2 months ago
BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that its special committee of the board of directors (the "Special Committee") has received an updated preliminary non-binding proposal letter (the "Proposal Letter"), dated April 2, 2025, from Dr. Wei-Wu He, Chairman of the board of directors and CEO of the Company, to acquire the entire business operations of the Company in China and all license-in, distribution and related rights in Asia (excluding Japan) related to certain pipeline products of the Company, including BI-1206, CID-103 and Thiotepa, for an aggregate purchase price of $20.0 million, which shall include assumption of approximately $20.0 million of indebtedness of the Company (the "Proposed Transaction"). The Proposal Letter updates the preliminary non-binding proposal letter submitted by Dr. He to the Company on June 21, 2024.
accessnewswire.com
2 months ago
BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, and provided an update on key highlights for 2024. Wei-Wu He, Ph.D.
accesswire.com
5 months ago
BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP) in China. "Dosing the first patient in our phase 1/2 study marks a significant milestone for both CID-103 program and chronic ITP patients who have limited treatment options," said Dr. Wei-Wu He, Chairman and CEO of CASI, "The rapid execution underscores our commitment to accelerating clinical development.
accesswire.com
6 months ago
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024. Dr. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases.
accesswire.com
7 months ago
BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to proceed with a phase 1/2 study of CID-103 in adults patients with chronic Immune Thrombocytopenia (ITP) in China. This China study is part of the global study that was approved by the US FDA in May 2024.
prnewswire.com
9 months ago
BEIJING , Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C.
See all news
